kist, it's been a long hard road to "turn the herd" (as some of...

kist, it's been a long hard road to "turn the herd" (as some of the long time shareholders say), a friend gave a very apt description that medicos world wide are "rusted on" to the old skin test.
The skin test is all they have had to test for TB for 100 years or more, the younger medicos are the ones who will adopt much quicker than their older compatriots.

Fascinating reading to read up on the changeover to blood testing, New York health aithorities have now changed over to the Cellestis blood test, San Francisco health have been using it for quite a while, Switzerland has changed over, etc, etc, it's only a matter of time. CST has done a lot of work in conjunction with the US armed forces who are very keen to adopt this TB blood test, the test itself lends itself to almost complete automation, something high on the agenda for US (and European) armed forces and larger users such as jails and health services all of whom continually have a TB detection problem.

A great read is the blog:-

http://quantiferon.blogspot.com/

a labour of love by a CST shareholder.

Maybe a few months ago at $3.50 odd it had too much hope priced into it but at these prices, with the prospects ahead, I believe it is very good buying.

Howver, once again, please DYOR.

regards, EB